Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib + paclitaxel in previously treated small cell lung cancer
2026-525382-47-00Phase 2Authorised
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of alisertib and paclitaxel in small cell lung cancer (SCLC), sponsored by Puma Biotechnology, Inc. Primary endpoint: Adverse events and serious adverse events. Planned start Sep 2026; status: authorised.
02
Drugs
alisertibpaclitaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2026-525382-47-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525382-47-00.